Vanda: EMA Positive Opinion for Imsidolimab in GPP

Key Takeaways

• The EMA's orphan medicines committee backed orphan designation for imsidolimab in GPP, an EU first for the disease.
• Imsidolimab is a humanized IgG4 monoclonal antibody that blocks interleukin-36 receptor signaling.
• Orphan status in the EU brings protocol assistance, reduced fees, and post-approval market exclusivity.
• An FDA decision on the imsidolimab BLA carries a target action date of December 12, 2026.

Imsidolimab and GPP at a glance

Field	Detail
Drug	Imsidolimab, an anti–IL-36 receptor monoclonal antibody
Company	Vanda Pharmaceuticals (Nasdaq: VNDA)
Indication	Generalized pustular psoriasis (GPP)
EU status	COMP positive opinion recommending orphan designation
US status	BLA under FDA review; target action date December 12, 2026
Other regions	Orphan status already granted in the United States and Japan

What did the EMA decide?

The Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency adopted a positive opinion recommending orphan drug designation for imsidolimab in GPP, Vanda Pharmaceuticals (Nasdaq: VNDA) said. The company called it the first time the EMA has recognized GPP as a distinct orphan disease in the EU, according to Vanda's July 16 press release.

A COMP positive opinion is a recommendation. The European Commission issues the final orphan designation decision, usually within about a month of the committee's opinion.

What is generalized pustular psoriasis?

GPP is a severe, chronic skin disease that can be life-threatening. It is not the same as plaque psoriasis. It differs in both its genes and its symptoms. The disease is driven by a faulty interleukin-36 (IL-36) signaling pathway. Patients can develop pustules across the body and body-wide inflammation. Severe cases raise the risk of death, as reviewed in the dermatology literature on GPP as a rare disease.

How does imsidolimab work?

Imsidolimab is a lab-made antibody, a humanized IgG4 monoclonal antibody. It blocks the IL-36 receptor. Many GPP patients lack a natural brake on IL-36 signaling. The drug is meant to correct that gap. Trial data on how well it works, and how safe it is, were published in NEJM Evidence in 2026.

What orphan designation means in the EU

The EMA grants orphan designation to medicines for rare, serious conditions. These must affect fewer than 5 in 10,000 people in the EU. Sponsors then gain protocol assistance, lower fees, and a period of market exclusivity after approval, according to the EMA's orphan designation overview.

What comes next for imsidolimab?

The EU recommendation follows similar orphan status in the United States and Japan. Meanwhile, the imsidolimab Biologics License Application for GPP sits under FDA review. The target action date is December 12, 2026. A US decision would set the near-term path. The EU designation supports later European development.

What remains unproven?

Orphan designation is a regulatory and incentive status, not a marketing approval. It does not confirm that imsidolimab will clear EU review or reach patients. The timing of the European Commission decision is not yet set. Any future marketing application will follow the standard EMA process.

Related NovaPharma coverage

• EMA board backs Ebola response and flags its 2025 annual report
• PRAC June 2026 highlights: valproate signal review and label update
• Truqap wins US approval in PTEN-deficient metastatic prostate cancer

Frequently Asked Questions

Primary Sources

1. Vanda Pharmaceuticals — EMA positive opinion for imsidolimab orphan designation (July 16, 2026)
2. EMA — orphan designation overview
3. Generalized pustular psoriasis: the case for rare disease and orphan designation